

Communication

# Highly Virulent and Multidrug-Resistant *Escherichia Coli* Sequence Type 58 from A Sausage in Germany

Elias Eger <sup>1</sup>, Marielle Domke <sup>2</sup>, Stefan E. Heiden <sup>2</sup>, Madeleine Paditz <sup>2</sup>, Veronika Balau <sup>3</sup>, Christiane Huxdorff <sup>4</sup>, Dirk Zimmermann <sup>4</sup>, Timo Homeier-Bachmann <sup>5</sup>, and Katharina Schaufler <sup>1,2,\*</sup>

<sup>1</sup> Institute of Infection Medicine, Christian-Albrecht University Kiel and University Medical Center Schleswig-Holstein, 24105 Kiel, Germany

<sup>2</sup> Pharmaceutical Microbiology, Institute of Pharmacy, University of Greifswald, 17489 Greifswald, Germany

<sup>3</sup> Institute of Medical Diagnostics, IMD Laboratory Greifswald, 17493 Greifswald, Germany

<sup>4</sup> Greenpeace e.V., 20547 Hamburg, Germany

<sup>5</sup> Institute of Epidemiology, Friedrich Loeffler-Institut, 17493 Greifswald-Insel Riems, Germany

\* Correspondence: schaufler@infmed.uni-kiel.de

**Abstract:** Studies have previously described the occurrence of multidrug-resistant (MDR) *Escherichia coli* in human and veterinary medical settings, livestock, and, to a lesser extent, in the environment and food. While they mostly analyzed foodborne *E. coli* regarding phenotypic and sometimes genotypic antibiotic resistance and basic phylogenetic classification, we have limited understanding of the in vitro and in vivo virulence characteristics and global phylogenetic contexts of these bacteria. Here, we investigated an *E. coli* strain (PBIO3502) isolated from a pork sausage in Germany in 2021 in-depth. Whole-genome sequence analysis revealed sequence type (ST)58, which is an emerging international high-risk clonal lineage. In addition to its MDR phenotype that mostly matched the genotype, PBIO3502 demonstrated pronounced virulence features, including in vitro biofilm formation, siderophore secretion, serum resilience, and in vivo mortality in *Galleria mellonella* larvae. Along with the genomic analysis indicating close phylogenetic relatedness of our strain with publicly available, clinically relevant representatives of the same ST, these results suggest the zoonotic and pathogenic character of PBIO3502 with the potential to cause infection in humans and animals. Also, our study highlights the necessity of the One Health approach while integrating human, animal, and environmental health, as well as the role of meat products and food chains in the putative transmission of MDR pathogens.

**Keywords:** antimicrobial resistance; CTX-M-1; Enterobacteriaceae; *Escherichia coli*; extended-spectrum  $\beta$ -lactamase; food safety; Inc11; next-generation sequencing; One Health; virulence

## 1. Introduction

Multidrug-resistant (MDR) Enterobacteriaceae, such as *Escherichia coli*, which are non-susceptible to more than three classes of antibiotics [1], have been on the rise for years. They are not only found in human and veterinary clinics but also in livestock and related animal products. Therefore, they are an important component of the One Health approach [2, 3], which aims at increasing and/or preserving the well-being of human, animal, and environmental health. While most One Health reports in this research area focus on the distribution of antibiotic resistance and phylogenetic backgrounds such as sequence types (STs), little is known about phenotypic virulence traits in vitro and in vivo [4]. The latter is particularly important when considering the zoonotic nature of MDR *E. coli* from animal sources, which have the potential to infect humans, and vice versa. These pathogenic *E. coli* are divided into extraintestinal pathogenic *E. coli* (ExPEC) and intestinal pathogenic representatives (InPEC) [5], with the latter exhibiting obligate pathogenicity, and foodborne isolates potentially causing outbreaks, such as in Germany in 2011 [6, 7]. In contrast, ExPEC strains usually colonize the intestinal tract of humans and animals asymptotically but frequently cause infection outside the gut. ExPEC possess several

virulence factors (VFs) that enable adhesion, biofilm formation, resilience, and thus infection in human and/or animal hosts and are critical for bacterial pathogenicity. However, the exact contribution of foodborne MDR ExPEC to human and animal infection and colonization has not yet been established beyond doubt, as the differentiation between commensal *E. coli* and facultative ExPEC strains remains difficult when performing either geno- or phenotypic characterization alone [8].

Here, we report an extended-spectrum  $\beta$ -lactamase (ESBL)-producing *E. coli* isolated from a pork sausage in Germany that we investigated in-depth by whole-genome sequencing (WGS) and functional analyses. The aim of this study was to (i) identify the phylogenetic background of the food-derived strain and explore its phylogenetic relationship to other genomes of the same sequence type, and (ii) examine the repertoire of genotypic and phenotypic resistance- and virulence-associated features combining bioinformatics with multiple in vitro and in vivo assays.

## 2. Results

As part of a small screening study for which we analyzed various meat products (including fresh pork sausage) from several grocery stores in Germany in May 2021, we isolated the ESBL-producing *E. coli* strain PBIO3502, which was first verified by MALDI-TOF MS and subsequently analyzed in detail by WGS. WGS revealed that PBIO3502 belonged to ST58 (serotype O65:H16) and thus phylogroup B1, which includes mostly commensal but also some ExPEC and InPEC strains [9]. PBIO3502 carried plasmids with incompatibility group (Inc)FIA and IncI1, as well as Col plasmids. Plasmid multilocus sequence typing [10] revealed that the IncI1 plasmid was ST3 (clonal complex 3).

The presence of resistance genes was investigated using AMRFinderPlus [11] and revealed the presence of the ESBL gene *bla*<sub>CTX-M-1</sub> (Ambler class A) and a BlaEC family class C  $\beta$ -lactamase *bla*<sub>EC</sub> (98.67% identity to EC-15) in addition to genes conferring resistance to macrolides (*mdf(A)*, *mef(C)*, and *mph(G)*), streptomycin (*aadA5*), sulfonamides (*sul2*), and diaminopyrimidines (*dfrA17*). Our phenotypic analysis of antibiotic resistance was mostly consistent with the genotype (**Table 1**) and showed that PBIO3502 had an MDR phenotype [1]. Also, we noticed the presence of heavy metal resistance-associated genes (*terWZABCDE*) that enable resistance to tellurite. Usually, *E. coli* strains exhibit minimum inhibitory concentrations of tellurite of 1  $\mu\text{g mL}^{-1}$  [12], but PBIO3502 showed a 64-fold increased tolerance.

**Table 1.** Phenotypic and genotypic resistance profile of PBIO3502.

Antimicrobial category	Antimicrobial agent	MIC <sup>a</sup> [μg mL <sup>-1</sup> ]	S/R <sup>b</sup>	Genotype <sup>d</sup>
Aminopenicillin + β-lactamase inhibitor	Ampicillin/sulbactam	≥ 32/16	R	<i>bla<sub>EC</sub></i>
Ureidopenicillin + β-lactamase inhibitor	Piperacillin/tazobactam	≥ 128/4	R	<i>bla<sub>EC</sub></i>
Third generation cephalosporins	Cefotaxime	≥ 64	R	<i>bla<sub>CTX-M-1</sub></i>
	Ceftazidime	≥ 64	R	
Carbapenems	Meropenem	≤ 0.25	S	
Aminoglycosides	Gentamicin	≤ 0.5	S	
	Streptomycin	64	NA	<i>aadA5</i>
Fluoroquinolones	Ciprofloxacin	≤ 0.25	S	
Tetracyclines	Tetracycline	≤ 0.5	S <sup>c</sup>	
Folate pathway inhibitors	Trimethoprim/sulfamethoxazole	≥ 16/304	R	<i>dfrA17, sul2</i>
Phosphonic acids	Fosfomycin	≤ 16	S	


<sup>a</sup> MIC, minimum inhibitory concentration

<sup>b</sup> Interpretive categories according to EUCAST (The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0. 2022). S, susceptible; R, resistant; NA, not applicable.

<sup>c</sup> Result was interpreted according to the published breakpoints of the CLSI (Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 32<sup>nd</sup> edition. 2022).

<sup>d</sup> Prediction based on alignment of sequences from AMRFinderPlus database (threshold for coverage and identity, ≥ 80%).

Among the nearly 300 genes associated with *E. coli* virulence provided by the virulence factor database (VFDB) [13], PBIO3502 harbored several gene clusters mainly associated with adherence (CFA/I fimbriae, *cfaABCD/E*; *E. coli* common pilus, *ecpABCDER*; factor adherence *E. coli*, *fdeC*; Hsp60, *htpB*; immunogenic lipoprotein A, *ilpA*; type I fimbriae, *fimABCDEFGHIZ*; type IV pili, *vfr*), biofilm formation (alginate, *algU*; autoinducer-2, *luxS*; curli fibers, *csgABCDEFGG*), invasion (*ibeBC*, *ompA*, *traI*) iron uptake (aerobactin, *iucABCD*, *iutA*; enterobactin, *entABCDEFES*, *fepABCDEG*, *fes*; salmochelin, *iroB*), and motility (peritrichous flagella, *cheBRWYZ*, *flgBCDFGHI*, *flhABCD*, *fliAGIMPQR*, *motA*; polar flagella, *flmH*, *nueA*). Genes encoding Shiga toxin were not present. Given the potential zoonotic background of PBIO3502 and this large genomic set of VFs, we further characterized PBIO3502 in several phenotypic virulence-associated experiments (Figure 1).



**Figure 1.** PBIO3205 exhibits a highly virulent phenotype. (a) Biofilm formation on polystyrene surfaces as determined by crystal violet staining ( $n = 4$ ). Results are expressed as growth-adjusted specific biofilm formation. The line within the box marks the median value, while the boxplot represents the 25<sup>th</sup> to 75<sup>th</sup> percentile of the data set. The whiskers mark the minimum and maximum values, respectively. (b) Morphology of long-term colonies examining the expression of the biofilm-associated extracellular matrix components curli fibers and cellulose. Congo red was used to specifically stain curli fibers, and cellulose was visually interpreted based on the textured surface. PBIO1435 and W3110 were used as reference. (c) Cellulose formation was examined by staining with Calcofluor and measuring the fluorescence intensity of bound calcofluor ( $n = 3$ ). Results are given as mean values of fluorescence intensity and standard errors. (d) The extent of secreted siderophores is expressed as the mean of the percent unit of siderophore production and standard error ( $n = 3-5$ ). (e) Survival in 50% human serum ( $n = 3-5$ ). Results are given as means and standard errors of  $\log_2$  fold change in CFU mL<sup>-1</sup> after 4 hours of incubation in the presence of human serum. (f and g) Kaplan-Meier plot of mortality in the *Galleria mellonella* larvae infection model ( $n = 3$ ). Results are expressed as mean percent mortality after injection of 10<sup>4</sup> CFU per larva (f) and 10<sup>5</sup> CFU per larva, respectively. NC, negative control. PC, positive control.

Some bacterial populations are able to protect themselves from external stressors (e.g., UV radiation and antibiotic therapy) by forming a biofilm [14]. In addition, there is evidence that biofilm formation is a critical factor in infection development [15]. Therefore, we investigated the ability of PBIO3502 to form biofilms and analyzed whether

the strain formed curli fibers (bacterial amyloid fibers) and/or cellulose (polysaccharide structures), which are important biofilm- and thus virulence-associated features [16]. When compared to the strong biofilm producer *E. coli* W3110 (specific biofilm formation (SBF) median, 1.96), PBIO3502 showed high adhesiveness to the plastic surface of a 96-well plate (SBF median, 2.86; **Figure 1a**), which likely promotes biofilm formation on catheters [17], for example. In addition, PBIO3502 showed both curli and cellulose formation in the long-term colony. The dye used to assess the morphology of long-term colonies stains only the curli fibers, but not the cellulose structures [18]. The latter are interpreted visually based on the structured surface (**Figure 1b**). Calcofluor, which has a high affinity for cellulose [19], was used to obtain a (semi-) quantitative result on the cellulose formation of PBIO3502. Our strain showed pronounced cellulose formation indicated by high fluorescence intensities (**Figure 1c**).


Especially during infection but also for general growth and fitness, iron is an important element for pathogenic bacteria [20]. Since bacteria cannot produce iron themselves, they have to acquire it from their surroundings. Therefore, pathogens produce low-molecular iron-binding molecules (so-called siderophores) that chelate free extracellular iron(III) and are subsequently internalized by membrane receptors. We examined whether and to what extent PBIO3502 produced siderophores, and as shown in **Figure 1d**, PBIO3502 secreted large amounts of siderophores (mean, 87.25%). The extent of siderophores was 11.5-fold higher when compared to the negative control W3110.

Highly virulent *E. coli* representatives are capable of causing bacteremia [21] and therefore must compete with the host defense system (e.g., the complement system). Gram-negative bacteria use several different mechanisms to deal with the immune response provided by various mechanisms, such as capsule expression [22], down-regulation of envelope stress response pathways [23], and outer membrane surface modifications [24]. Therefore, we challenged this foodborne strain by incubation in 50% human serum for four hours. PBIO3502 was not inhibited by the complement-containing serum and was able to double its cell number (**Figure 1e**). This result again highlights the highly virulent and clinically relevant nature of PBIO3502.

In addition, we performed an infection model using larvae of the greater wax moth *Galleria mellonella* to investigate the ability of PBIO3502 to cause in vivo mortality. We injected  $10^4$  or  $10^5$  colony forming units (CFU) per larva. When  $10^4$ CFU were injected, a mortality rate of 6.7% was obtained after 24 hours (**Figure 1f**). This mortality rate increased up to 26.7% 72 hours after infection. The 10-fold increase in inoculation size resulted in an increase in the mortality rate up to 36.7% at 24 hours and 80.0% at 72 hours of infection (**Figure 1g**). These results were comparable to the mortality rates of a hypervirulent *K. pneumoniae* ST420 strain PBIO2030 isolated from a wound [25]. In conclusion, the findings demonstrate the virulent potential of PBIO3502.

Finally, to classify our strain in a more global perspective and again evaluate the zoonotic potential, we performed a phylogenetic comparison of overall 159 closely related, publicly available ST58 genomes and PBIO3502 (**Figure 2**).





**Figure 2.** Phylogenetics reveals close relationship of PBIO3502 with publicly available genomes ( $n = 159$ ). Included genomes were selected based on most shared k-mers using Mash. The phylogenetic tree was constructed using a maximum likelihood-based approach and is based on a core single-nucleotide polymorphism alignment (4,984 sites). The circular tree was midpoint-rooted and the circles on the branches indicate bootstrap support of  $\geq 50\%$  from 1,000 replicates. The labels indicate the accession number (except PBIO3502) and are colored according to their source/host, as indicated in the legend. Annotations indicate (from inner to outer circle): encoded CTX-M (cefotaximase) allele, presence of genes encoding aerobactin and tellurite resistance. NA, not applicable (i.e., no metadata provided).

The phylogenetic tree shows that the genomes grouped into multiple clades with several subclades. Dispersed across the clades, genomes originated from humans, livestock, companion and wild animals, food, and the environment. Note that PBIO3502 clustered with three genomes from livestock (ERR3393207, ERR7420888) and environmental sources (SRR13848069), respectively. Interestingly, these closely related strains were sampled from different European locations in different years and were mainly associated with pigs. For example, ERR7420888 (designated MSG45-C09) was isolated from a healthy pig on a commercial pig farm in the Midlands of the United Kingdom in 2015 [26], while SRR13848069 (designated 20-MO00084-0) originated from scalding water from a pig slaughterhouse in Germany in 2020 [27]. All genomes assigned

to the “PBIO3502 and ERR1055859 subclade” encoded aerobactin and tellurite resistance genes, a combination that was unique in the phylogenetic tree. Although PBIO3502 did not show immediate phylogenetic relatedness to human-derived strains and was in a clade primarily composed of strains from domestic and wild animals and the environment, our analysis demonstrates that phylogenetically related ST58 strains from humans were present in other clades. This again indicates the zoonotic character of the ST58 lineage and highlights the complex connections within the One Health continuum.

### 3. Discussion

A growing body of studies show the global spread of MDR *E. coli* and underline the clinical relevance of this pathogen, with nearly 60,000 deaths caused by antibiotic-resistant *E. coli* in 2019 alone [28]. In addition, MDR *E. coli* strains are commonly found in the environment, in animals (pets and livestock), and in meat products [2, 29–34]. Due to the worldwide increased meat consumption and the pressure on prices of processed foods, slaughterhouses have to operate in an economically-oriented high throughput, potentially leading to contamination of meat products and the water used with enteric pathogens of animal origin [35]. Therefore, it is not surprising that we and others have recently detected MDR *E. coli* strains in the wastewater of German slaughterhouses that are resistant even to the last-resort drug colistin [27, 36]. Also, contaminated meat products might foster the transmission of pathogens from animals to humans through the food chain, of which a confirmed MDR ExPEC outbreak in London (United Kingdom) in the mid-1980s [37–39] and the above-mentioned outbreak in Germany in 2011 are good examples. This underlines the interdependence of animal and human health and thus the need for the One Health approach. Although direct consumption of unprocessed fresh pork and poultry products is uncommon in Germany, putative foodborne ExPEC transmission involves ingestion of inadequately cooked meat or cross-contamination in the kitchen during food handling, potentially, for example, resulting in wound infection [40, 41].

The establishment and frequent application of next-generation sequencing technologies have demonstrated that the spread of MDR *E. coli* appears to be driven by a limited number of pandemic STs such as ST131, ST648, or ST410 [42–44]. These pathogenic clonal lineages successfully combine multidrug resistance and high virulence. However, other successful clonal ExPEC lineages such as ST58 (which belongs to clonal complex 87 [45]) increasingly emerge as globally disseminated pathogens. Unlike most pandemic ExPEC lineages, which are mostly associated with phylogroups B2 or D, ST58 belongs to phylogroup B1. Interestingly, this phylogroup contains only a small number of phylogroup-specific core genes compared to other phylogroups, indicating high diversity within this phylogroup [46]. Here, we describe a foodborne *E. coli* ST58 strain that exhibits pronounced in vitro and in vivo virulence properties required for pathogenicity and bacterial survival, indicating the great potential to actually cause infection in humans and animals upon successful transmission. While the direct transfer of *E. coli* ST58 strains via the food chain has not yet been confirmed beyond doubt [4, 47] and is also not within the scope of this study, it has been previously suggested that ST58 shows high clonality among strains originating from humans, animals, and the environment [48–50]. Our phylogenetic analysis comparing global ST58 genomes supports the latter and reiterates the clinical and zoonotic relevance of our strain. However, we used a limited number of genomes in this study. Future investigations will need to address this further and provide a more comprehensive phylogenetic and epidemiologic picture of this (putatively) successful, emerging clonal lineage.

Many resistance genes, but especially ESBL enzymes, are often encoded on plasmids, which allows rapid resistance transfer among different bacteria and thus widespread dissemination [51]. Interestingly, PBIO3502 carried an IncI1 plasmid, which appears to be a common plasmid type of InPEC strains, but also, to a lesser extent, occurs in ExPEC [52]. Moreover, ST3 IncI1 plasmids are not only frequently found in strains isolated from

humans, but also in pathogens of animal origin [53]. This is further evidence of the zoonotic character of PBIO3502.

#### 4. Materials and Methods

##### *Strain origin and general methods*

As part of a small screening study, packaged fresh meat samples from various grocery stores were tested for different MDR bacteria. Briefly, the meat samples were opened under sterile conditions, two pieces of approximately 5 mm<sup>3</sup> were cut out with a sterile scalpel (Braun, Melsungen, Germany) and transferred to 5 mL of tryptic soy broth (Carl Roth, Karlsruhe, Germany). The bacteria were then enriched under shaking conditions (130 rpm) at 37°C overnight. Then, 100 µL of the bacterial suspension was plated onto different chromogenic selection plates and incubated overnight at 37°C. The strain 27-ESBL-EC (internal designation PBIO3502) was cultivated on a CHROM-ESBL selection plate (Mast Diagnostica GmbH, Reinfeld, Germany) and the species *E. coli* was confirmed using MALDI-TOF MS (Bruker, Bremen, Germany). It was derived from a fresh bratwurst purchased from a German grocery store. All strains were stored at -80°C in lysogeny broth (LB; Carl Roth, Karlsruhe, Germany) supplemented with 20% (*v/v*) glycerol (anhydrous; Merck, Darmstadt, Germany). Prior to use, one single colony of fresh overnight cultures on LB agar plates was inoculated in 5 mL of LB and grown under shaking conditions (130 rpm) at 37°C overnight.

##### *Whole-genome sequencing*

Total DNA was extracted using the MasterPure DNA Purification Kit for Blood, v. 2 (Lucigen, Middleton, WI, USA), according to the manufacturer's instructions. The isolated DNA was quantified fluorometrically using the Qubit 4 fluorometer and the corresponding dsDNA HS Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). DNA was shipped to the Microbial Genome Sequencing Center (MiGS), now SeqCenter (Pittsburgh, PA, USA), and after library preparation using the Illumina DNA Prep Kit and IDT 10bp UDI indices (Illumina, San Diego, CA, USA) sequenced on an Illumina NextSeq 2000, producing 2 × 151 bp reads. Demultiplexing, quality control, and adapter trimming were performed using bcl-convert v. 3.9.3 [54].

##### *Sequence assembly and genomic analyses*

Short-read data were processed using BBDuk from BBTools v. 38.95 (<https://sourceforge.net/projects/bbmap/>) to trim the adapters, filter possible PhiX contaminants, and do further quality- and polymer-trimming. Quality control (QC) of provided (raw) and processed (trimmed) reads was performed using FastQC v. 0.11.9 (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). Trimmed reads were assembled using shovill v. 1.1.0 (<https://github.com/tseemann/shovill>) with SPAdes v. 3.15.3 [55]. An additional polishing step (besides the one implemented in the shovill assembly pipeline) was performed by first mapping the trimmed reads to the assembly using BWA v. 0.7.17 [56]. The alignment files were then converted to binary format, sorted, and duplicate reads were marked with SAMtools v. 1.14 [57]. Finally, the draft contigs were corrected using Pilon v. 1.24 [58]. Genome completeness and contamination were assessed using CheckM v. 1.1.3 [59]. Prokka v. 1.14.6 [60] was used to automatically annotate the draft assembly. Genomic analyses including in silico multi-locus sequence typing, serotype prediction, and antibiotic resistance and virulence feature detection were performed using mlst v. 2.19.0 (<https://github.com/tseemann/mlst>; with PubMLST [61] database and Enterobase [62]), ABRicate v. 1.0.0 (<https://github.com/tseemann/abricate>; with ResFinder [63], PlasmidFinder [10], VFDB [13], BacMet2 [64] and EcoH [65] databases), and AMRFinderPlus v. 3.10.30 with database v. 2022-05-26.1 [11]. Assignment to the phylogroup was performed using ClermonTyping v. 20.03 [66].



### Phylogeny

For the creation of a core single-nucleotide polymorphism (SNP)-based phylogeny of closely related isolates, Enterobase [62] was searched for *E. coli* ST58 strains ( $n = 2,199$ ) for which paired Illumina read data were available ( $n = 2,186$ ). Data were downloaded from the public European Nucleotide Archive SRA FTP server (<ftp://ftp.sra.ebi.ac.uk/vol1/>). Mash v. 2.3 [67] was used to generate sketches (k-mer size, 21; sketch size, 1,000,000; minimum number of k-mers for reads, 3) of the reference sequence (draft genome of PBIO3502) and the public raw read data. Afterwards the distance between the reference sketch and the query raw read sketches was estimated and the 200 read sets with the shortest distance (most shared k-mers) selected. For these accessions, read trimming, genome assembly, and analyses were performed as described above. The trimmed reads were mapped against the draft genome of PBIO3502 using snippy v. 4.6.0 (<https://github.com/tseemann/snippy>) to create a whole-genome alignment with 201 sequences. The alignment was processed using Gubbins v. 3.2.1 [68] to filter out regions with SNPs that are likely the result of recombination. In this step, two isolates were removed due to alignment gaps or missing information at more than 25% of the alignment sites. The alignment of the remaining sequences ( $n = 199$ ) was processed using snp-sites v. 2.5.1 [69] to retain only alignment positions containing A, C, G, or T exclusively. A maximum likelihood tree was inferred with RAxML-NG v. 1.1.0 [70] using GTR+G by first parsing the alignment and excluding 40 sequences that were completely identical to another sequence. The final alignment (containing 159 sequences and 4,984 sites) was then processed by searching 500 parsimony and 500 random starting trees and performing 1,000 bootstrap repeats. The best-scoring maximum likelihood tree was midpoint-rooted in iTOL v. 6.5.7 [71] and visualized with bootstrap support values and metadata. The exported graphic was post-processed using Affinity Designer v. 1.10.5.1342 (<https://affinity.serif.com/en-us/designer/>).

### Minimum inhibitory concentration

Phenotypic antimicrobial susceptibility testing was performed in collaboration with the IMD Laboratory Greifswald (Germany) using the automated VITEK 2 system (bioMérieux, Marcy l'Etoile, France). Testing was performed using AST-N389 card, according to the manufacturer's instructions. MIC values of gentamicin (Carl Roth, Karlsruhe, Germany), streptomycin (Sigma-Aldrich, St. Louis, MO, USA), tetracycline (Carl Roth, Karlsruhe, Germany), and tellurite (Alfa Aesar, Haverhill, MA, USA) were determined by broth microdilution according to ISO Standard 20776-1 [72]. Briefly, several single colonies were resuspended in a 0.9% (*w/v*) NaCl solution until the corresponding suspensions had an OD<sub>600</sub> equal to 0.5 McFarland standard turbidity. The bacterial suspensions were then diluted 1:230 in cation-adjusted Mueller-Hinton broth 2 (MH-2; Sigma-Aldrich, St. Louis, MO, USA), corresponding to approximately 10<sup>5</sup> CFU mL<sup>-1</sup>. Serial 2-fold dilutions were performed in a 96-well plate (Sarstedt, Nümbrecht, Germany) with concentrations ranging from 64 to 0.5 µg mL<sup>-1</sup> for the antibiotics gentamicin, streptomycin, and tetracycline and from 512 to 0.5 µg mL<sup>-1</sup> for the heavy metal tellurite, respectively. Finally, the bacterial suspensions were added and incubated at 37 °C for 18 ± 2 hours. The MIC represents the lowest concentration of antimicrobial agent that inhibits visible bacterial growth.

### Biofilm formation

Biofilm formation on polystyrene surfaces was determined by crystal violet (CV) staining as previously described [73, 74] with some adjustments. First, overnight cultures were diluted 100-fold in 5 mL of fresh M9 minimal salt medium (MP Biomedicals, Irvine, CA, USA) containing 0.4% (*w/v*) glucose (Carl Roth, Karlsruhe, Germany) and incubated at 37 °C and 130 rpm until OD<sub>600</sub> reached 0.5 McFarland standard turbidity. The bacterial suspensions were then diluted 1:10 and 200 µL were then transferred in triplicate to a 96-well flat bottomed polystyrene plate (Nunc, Thermo Fisher Scientific, Waltham, MA,

USA). In addition, three control wells were filled with 200  $\mu\text{L}$  of sterile medium. The plates were hermetically sealed and incubated at 28°C for 24 hours without shaking. Subsequently,  $\text{OD}_{600}$  was measured using CLARIOstar Plus (BMG LABTECH GmbH, Ortenberg, Germany), planktonic cells were removed by washing three times with deionized water, and the microtiter plates were air-dried for 10 minutes. After fixation with 250  $\mu\text{L}$  of 99% (*v/v*) methanol (Merck, Darmstadt, Germany) for 15 minutes and air-drying, the cells were stained with 250  $\mu\text{L}$  of a 0.1% (*w/v*) aqueous CV solution (Sigma-Aldrich, St. Louis, MO, USA) for 30 minutes. The staining solution was then discarded and unbound dye was removed by washing three times with deionized water. After air-drying for 10 minutes, the bound CV was dissolved with a mixture of 80 parts ethanol (99.8% (*v/v*); Carl Roth, Karlsruhe, Germany) and 20 parts acetone (Merck, Darmstadt, Germany) at room temperature (rt) with horizontal shaking at 200 rpm for 30 minutes. After complete dissolution, 125  $\mu\text{L}$  were transferred to a new microtiter plate and optical density was measured at a wavelength of 570 nm using the plate reader. The strength of biofilm formation was expressed as specific biofilm formation (SBF). The SBF was calculated according to the following formula [75]:  $\text{SBF} = (\text{B} - \text{NC}) / \text{G}$ , where B is the  $\text{OD}_{570}$  of the stained bacteria, NC is the  $\text{OD}_{570}$  of the stained control wells to eliminate the fraction of CV adhering to the polystyrene surface due to abiotic factors, and G is the  $\text{OD}_{600}$  representing the density of cells grown in the media.

The expression of biofilm-associated extracellular matrix components such as cellulose and curli fibers was tested using macrocolony assays as previously described [73]. Five microliters of overnight culture were dropped onto span agar plates (Hellmuth Carroux, Hamburg, Germany). The plates were hermetically sealed and incubated at 28°C for 5 days. For detection of curli fimbriae, 0.005% Congo red and 0.0025% Coomassie Brilliant Blue G-250 (both chemicals were purchased from Carl Roth, Karlsruhe, Germany) were added to the span agar and evaluated visually. For cellulose staining, the span agar contained 0.004% Calcofluor (Sigma-Aldrich, St. Louis, MO, USA) and the extent of cellulose formation was measured by fluorescence intensity using the plate reader (excitation, 400–415 nm, emission, 480–520 nm).

#### *Siderophore production assay*

Quantification of the extent of siderophores secreted by PBIO3502 was performed according to a previously published protocol [23]. Briefly, the adjusted bacterial suspensions were diluted and grown in 5 mL of chelated M9 minimal medium supplemented with casamino acids (c-M9-CA) at 37°C and 130 rpm for 24 hours. The c-M9-CA consisted of the following compounds: M9 minimal salt medium (MP Biomedicals, Irvine, CA, USA), 2 mM  $\text{MgSO}_4$  (Carl Roth, Karlsruhe, Germany), 200  $\mu\text{M}$  2,2'-dipyridyl (Carl Roth, Karlsruhe, Germany), and 0.3% (*w/v*) casamino acids (BD, Franklin Lakes, NJ, USA). After incubation, 1 mL of the bacterial cultures were centrifuged (4,900  $\times g$  for 20 minutes at rt) and 100  $\mu\text{L}$  of the siderophore-containing supernatant were transferred in triplicate to 96-well microtiter plates (Nunc, Thermo Fisher Scientific, Waltham, MA, USA) with 100  $\mu\text{L}$  of chrome azurol S shuttle solution (composition according to [76]) already in the wells. Wells containing only fresh medium and 15 mM EDTA (Carl Roth, Karlsruhe, Germany) served as blank and positive control, respectively. The non-siderophore producer W3110 served as a negative control. All mixtures were incubated in the dark at rt for 30 minutes. Finally, absorbance was measured at a wavelength of 630 nm using the plate reader. Secretion of siderophores was calculated as previously described [77] and expressed as a percentage unit of siderophore production.

#### *Serum resistance*

Determination of survival in 50% human serum was performed as previously described [23]. Briefly, overnight cultures were diluted 1:100 in 5 mL of fresh LB and incubated with shaking at 37°C until  $\text{OD}_{600}$  reached 0.5 McFarland standard turbidity. Then 1000  $\mu\text{L}$  of the bacterial suspension was pelleted (7,500  $\times g$  for 5 minutes at rt) and

resuspended in 1 mL of phosphate-buffered saline (PBS; Thermo Fisher Scientific, Waltham, MA, USA). One hundred microliters of the sample were seeded in a 96-well microtiter plate containing 100  $\mu\text{L}$  of human serum (United States origin; Sigma-Aldrich, St. Louis, MO, USA) per well (resulting in a final concentration of 50% human serum and approximately  $10^8 \text{CFU mL}^{-1}$ ). Following this, 20  $\mu\text{L}$  of each sample was withdrawn and serial dilutions were plated on LB agar plates and incubated overnight at  $37^\circ\text{C}$  to determine the size of the inoculum. The inoculated microtiter plates were incubated for 4 hours at  $37^\circ\text{C}$  without agitation. Thereafter, the number of surviving  $\text{CFU mL}^{-1}$  was determined by plating out serial dilutions and incubating at  $37^\circ\text{C}$  overnight. The positive control in each experiment was the serum-resistant PBIO1289 (initially designated as IMT10740 [78, 79]). The serum-sensitive W3110 served as the negative control. Serum resistance was expressed as  $\log_2$  fold change in  $\text{CFU mL}^{-1}$  after treatment with respect to inoculum size.

#### *Infection of Galleria mellonella larvae*

Infections of larvae of the greater wax moth *G. mellonella* were performed as previously described [23]. Overnight cultures were diluted 1:100 in 30 mL of fresh LB and incubated with shaking at  $37^\circ\text{C}$  to an  $\text{OD}_{600}$  of 1.0. Then 1000  $\mu\text{L}$  of the bacterial suspension were pelleted (16,000  $\times g$  for 5 minutes at rt) and washed twice with PBS. The bacterial suspensions were diluted to  $10^6 \text{CFU mL}^{-1}$  and  $10^7 \text{CFU mL}^{-1}$ , respectively. Larvae (proinsects, Minden, Germany) were randomly divided into groups of 10 individuals each and 10  $\mu\text{L}$  of the adjusted bacterial suspensions were injected into the left proleg. In addition, 10  $\mu\text{L}$  of PBS was injected into a group of larvae to ensure that death was not due to trauma from the injection. Each group was placed in 90-mm glass Petri dishes, kept at  $37^\circ\text{C}$  in the dark, and death was recorded every 24 hours. Individuals were considered dead when they no longer responded to physical stimuli and showed pigmentation. The results of three independent tests were pooled for each strain to generate Kaplan-Meier plots of mortality rates [80].

#### *Data visualization and analysis*

Data visualization was performed using GraphPad Prism v. 9.3.1 for macOS (GraphPad Software, San Diego, CA, USA). All experiments were performed with three or more independent biological replicates. Unless otherwise specified, data were expressed as mean and standard error.

## 5. Conclusions

The finding of a highly virulent and MDR, foodborne *E. coli* ST58, which was phylogenetically related to clinical strains of the same ST suggests its zoonotic and pathogenic potential and the relevance of the One Health approach. Also, our study highlights the potential role of food (chains) in the spread and putative transmission of MDR pathogens.

**Author Contributions:** Conceptualization, E.E. and K.S.; methodology, E.E. and S.H.; software, S.H.; validation, E.E.; formal analysis, C.H., D.Z., E.E., K.S., S.H., T.H., M.P., M.S. and V.B.; investigation, E.E., M.P., M.S. and V.B.; resources, C.H., D.Z. and TH; data curation, E.E. and M.S.; writing—original draft preparation, E.E.; writing—review and editing, K.S.; visualization, E.E. and S.H.; supervision, K.S.; project administration, K.S.; funding acquisition, K.S. and T.H. All authors have read and agreed to the published version of the manuscript.

**Funding:** The APC was funded by Land Schleswig-Holstein within the funding programme Open Access Publikationsfonds.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data for this study have been deposited in the European Nucleotide Archive (ENA) at EMBL-EBI under accession number PRJEB53849 (<https://www.ebi.ac.uk/ena/browser/view/PRJEB53849>).

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Magiorakos, A.P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; Paterson, D.L.; Rice, L.B.; Stelling, J.; Struelens, M.J.; Vatopoulos, A.; Weber, J.T.; Monnet, D.L. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. *Clinical Microbiology and Infection* **2012**, *18*, 268–281, doi: 10.1111/j.1469-0691.2011.03570.x.
2. Ewers, C.; Bethe, A.; Semmler, T.; Guenther, S.; Wieler, L.H. Extended-spectrum beta-lactamase-producing and AmpC-producing *Escherichia coli* from livestock and companion animals, and their putative impact on public health: A global perspective. *Clinical Microbiology and Infection* **2012**, *18*, 646–655, doi: 10.1111/j.1469-0691.2012.03850.x.
3. White, A.; Hughes, J.M. Critical importance of a One Health approach to antimicrobial resistance. *Ecohealth* **2019**, *16*, 404–409, doi: 10.1007/s10393-019-01415-5.
4. Manges, A.R. *Escherichia coli* and urinary tract infections: The role of poultry-meat. *Clinical Microbiology and Infection* **2016**, *22*, 122–129, doi: 10.1016/j.cmi.2015.11.010.
5. Kaper, J.B.; Nataro, J.P.; Mobley, H.L. Pathogenic *Escherichia coli*. *Nature Reviews Microbiology* **2004**, *2*, 123–140, doi: 10.1038/nrmicro818.
6. Buchholz, U.; Bernard, H.; Werber, D.; Bohmer, M.M.; Remschmidt, C.; Wilking, H.; Delere, Y.; an der Heiden, M.; Adlhoch, C.; Dreesman, J.; Ehlers, J.; Ethelberg, S.; Faber, M.; Frank, C.; Fricke, G.; Greiner, M.; Hohle, M.; Ivarsson, S.; Jark, U.; Kirchner, M.; Koch, J.; Krause, G.; Lubber, P.; Rosner, B.; Stark, K.; Kuhne, M. German outbreak of *Escherichia coli* O104:H4 associated with sprouts. *The New England Journal of Medicine* **2011**, *365*, 1763–1770, doi: 10.1056/NEJMoa1106482.
7. Bielaszewska, M.; Mellmann, A.; Zhang, W.; Köck, R.; Fruth, A.; Bauwens, A.; Peters, G.; Karch, H. Characterisation of the *Escherichia coli* strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: A microbiological study. *The Lancet Infectious Diseases* **2011**, *11*, 671–676, doi: 10.1016/S1473-3099(11)70165-7.
8. Day, M.; Hopkins, K.; Wareham, D.; Toleman, M.; Elviss, N.; Randall, L.; Teale, C.; Cleary, P.; Wiuff, C.; Doumith, M.; Ellington, M.; Woodford, N.; Livermore, D. Extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* in human-derived and foodchain-derived samples from England, Wales, and Scotland: an epidemiological surveillance and typing study. *The Lancet Infectious Diseases* **2019**, *19*, 1325–1335, doi: 10.1016/S1473-3099(19)30273-7.
9. Denamur, E.; Clermont, O.; Bonacorsi, S.; Gordon, D. The population genetics of pathogenic *Escherichia coli*. *Nature Reviews Microbiology* **2021**, *19*, 37–54, doi: 10.1038/s41579-020-0416-x.
10. Carattoli, A.; Zankari, E.; Garcia-Fernandez, A.; Voldby Larsen, M.; Lund, O.; Villa, L.; Moller Aarestrup, F.; Hasman, H. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrobial Agents and Chemotherapy* **2014**, *58*, 3895–3903, doi: 10.1128/AAC.02412-14.
11. Feldgarden, M.; Brover, V.; Gonzalez-Escalona, N.; Frye, J.G.; Haendiges, J.; Haft, D.H.; Hoffmann, M.; Pettengill, J.B.; Prasad, A.B.; Tillman, G.E.; Tyson, G.H.; Klimke, W. AMRFinderPlus and the Reference Gene Catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence. *Scientific Reports* **2021**, *11*, 12728, doi: 10.1038/s41598-021-91456-0.
12. Taylor, D.E. Bacterial tellurite resistance. *Trends in Microbiology* **1999**, *7*, 111–115, doi: 10.1016/s0966-842x(99)01454-7.
13. Liu, B.; Zheng, D.; Zhou, S.; Chen, L.; Yang, J. VFDB 2022: A general classification scheme for bacterial virulence factors. *Nucleic Acids Research* **2022**, *50*, D912–D917, doi: 10.1093/nar/gkab1107.
14. Van Houdt, R.; Michiels, C.W. Role of bacterial cell surface structures in *Escherichia coli* biofilm formation. *Research in Microbiology* **2005**, *156*, 626–633, doi: 10.1016/j.resmic.2005.02.005.
15. Ciofu, O.; Moser, C.; Jensen, P.O.; Hoiby, N. Tolerance and resistance of microbial biofilms. *Nature Reviews Microbiology* **2022**, doi: 10.1038/s41579-022-00682-4.
16. Bokranz, W.; Wang, X.; Tschape, H.; Romling, U. Expression of cellulose and curli fimbriae by *Escherichia coli* isolated from the gastrointestinal tract. *Journal of Medical Microbiology* **2005**, *54*, 1171–1182, doi: 10.1099/jmm.0.46064-0.
17. Wilks, S.A.; Koerfer, V.V.; Prieto, J.A.; Fader, M.; Keevil, C.W. Biofilm development on urinary catheters promotes the appearance of viable but nonculturable bacteria. *mBio* **2021**, *12*, doi: 10.1128/mBio.03584-20.
18. Reichhardt, C.; Jacobson, A.N.; Maher, M.C.; Uang, J.; McCrate, O.A.; Eckart, M.; Cegelski, L. Congo red interactions with curli-producing *E. coli* and native curli amyloid fibers. *PLOS One* **2015**, *10*, e0140388, doi: 10.1371/journal.pone.0140388.
19. Serra, D.O.; Richter, A.M.; Hengge, R. Cellulose as an architectural element in spatially structured *Escherichia coli* biofilms. *Journal of Bacteriology* **2013**, *195*, 5540–5554, doi: 10.1128/JB.00946-13.
20. Page, M.G.P. The role of iron and siderophores in infection, and the development of siderophore antibiotics. *Clinical Infectious Diseases* **2019**, *69*, S529–S537, doi: 10.1093/cid/ciz825.
21. Denamur, E.; Condamine, B.; Esposito-Farese, M.; Royer, G.; Clermont, O.; Laouenan, C.; Lefort, A.; de Lastours, V.; Galardini, M.; Colibafii, groups, S. Genome wide association study of *Escherichia coli* bloodstream infection isolates identifies genetic determinants for the portal of entry but not fatal outcome. *PLOS Genetics* **2022**, *18*, e1010112, doi: 10.1371/journal.pgen.1010112.



22. Whitfield, C. Biosynthesis and assembly of capsular polysaccharides in *Escherichia coli*. *Annual Review of Biochemistry* **2006**, *75*, 39–68, doi: 10.1146/annurev.biochem.75.103004.142545.
23. Eger, E.; Schwabe, M.; Schulig, L.; Hübner, N.-O.; Bohnert, J.A.; Bornscheuer, U.T.; Heiden, S.E.; Müller, J.U.; Adnan, F.; Becker, K.; Correa-Martinez, C.L.; Guenther, S.; Idelevich, E.A.; Baecker, D.; Schaufler, K. Extensively drug-resistant *Klebsiella pneumoniae* counteracts fitness and virulence costs that accompanied ceftazidime-avibactam resistance acquisition. *Microbiology Spectrum* **2022**, e0014822, doi: 10.1128/spectrum.00148-22.
24. Phan, M.D.; Peters, K.M.; Sarkar, S.; Lukowski, S.W.; Allsopp, L.P.; Gomes Moriel, D.; Achard, M.E.; Totsika, M.; Marshall, V.M.; Upton, M.; Beatson, S.A.; Schembri, M.A. The serum resistome of a globally disseminated multidrug resistant uropathogenic *Escherichia coli* clone. *PLOS Genetics* **2013**, *9*, e1003834, doi: 10.1371/journal.pgen.1003834.
25. Eger, E.; Heiden, S.E.; Becker, K.; Rau, A.; Geisenhainer, K.; Idelevich, E.A.; Schaufler, K. Hypervirulent *Klebsiella pneumoniae* sequence type 420 with a chromosomally inserted virulence plasmid. *International Journal of Molecular Sciences* **2021**, *22*, doi: 10.3390/ijms22179196.
26. AbuOun, M.; O'Connor, H.M.; Stubberfield, E.J.; Nunez-Garcia, J.; Sayers, E.; Crook, D.W.; Smith, R.P.; Anjum, M.F. Characterizing antimicrobial resistant *Escherichia coli* and associated risk factors in a cross-sectional study of pig farms in Great Britain. *Frontiers in Microbiology* **2020**, *11*, doi: 10.3389/fmicb.2020.00861.
27. Savin, M.; Bierbaum, G.; Kreyenschmidt, J.; Schmithausen, R.M.; Sib, E.; Schmoger, S.; Kasbohrer, A.; Hammerl, J.A. Clinically relevant *Escherichia coli* isolates from process waters and wastewater of poultry and pig slaughterhouses in Germany. *Microorganisms* **2021**, *9*, doi: 10.3390/microorganisms9040698.
28. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. *The Lancet* **2022**, *399*, 629–655, doi: 10.1016/S0140-6736(21)02724-0.
29. Manges, A.R.; Johnson, J.R. Food-borne origins of *Escherichia coli* causing extraintestinal infections. *Clinical Infectious Diseases* **2012**, *55*, 712–719, doi: 10.1093/cid/cis502.
30. Ibrahim, D.R.; Dodd, C.E.; Stekel, D.J.; Ramsden, S.J.; Hobman, J.L. Multidrug resistant, extended spectrum beta-lactamase (ESBL)-producing *Escherichia coli* isolated from a dairy farm. *FEMS Microbiology Ecology* **2016**, *92*, fiw013, doi: 10.1093/femsec/fiw013.
31. Pietsch, M.; Irrgang, A.; Roschanski, N.; Brenner Michael, G.; Hamprecht, A.; Rieber, H.; Kasbohrer, A.; Schwarz, S.; Rosler, U.; Kreienbrock, L.; Pfeifer, Y.; Fuchs, S.; Werner, G.; RESET Study Group. Whole genome analyses of CMY-2-producing *Escherichia coli* isolates from humans, animals and food in Germany. *BMC Genomics* **2018**, *19*, 601, doi: 10.1186/s12864-018-4976-3.
32. Bergspica, I.; Kaprou, G.; Alexa, E.A.; Prieto, M.; Alvarez-Ordóñez, A. Extended spectrum beta-lactamase (ESBL) producing *Escherichia coli* in pigs and pork meat in the European Union. *Antibiotics* **2020**, *9*, doi: 10.3390/antibiotics9100678.
33. Eger, E.; Heiden, S.E.; Korolew, K.; Bayingana, C.; Ndoli, J.M.; Sendegeya, A.; Gahutu, J.B.; Kurz, M.S.E.; Mockenhaupt, F.P.; Müller, J.; Simm, S.; Schaufler, K. Circulation of extended-spectrum beta-lactamase-producing *Escherichia coli* of pandemic sequence types 131, 648, and 410 among hospitalized patients, caregivers, and the community in Rwanda. *Frontiers in Microbiology* **2021**, *12*, 662575, doi: 10.3389/fmicb.2021.662575.
34. Weber, L.P.; Dreyer, S.; Heppelmann, M.; Schaufler, K.; Homeier-Bachmann, T.; Bachmann, L. Prevalence and risk factors for ESBL/AmpC-*E. coli* in pre-weaned dairy calves on dairy farms in Germany. *Microorganisms* **2021**, *9*, doi: 10.3390/microorganisms9102135.
35. Sofos, J.N. Challenges to meat safety in the 21st century. *Meat Science* **2008**, *78*, 3–13, doi: 10.1016/j.meatsci.2007.07.027.
36. Homeier-Bachmann, T.; Heiden, S.E.; Lubcke, P.K.; Bachmann, L.; Bohnert, J.A.; Zimmermann, D.; Schaufler, K. Antibiotic-resistant Enterobacteriaceae in wastewater of abattoirs. *Antibiotics* **2021**, *10*, doi: 10.3390/antibiotics10050568.
37. Phillips, I.; King, A.; Rowe, B.; Gross, R.J.; Eykyn, S.; Gransden, W.R.; Frost, J.A. Epidemic multiresistant *Escherichia coli* infection in West Lambeth Health District. *The Lancet* **1988**, *1*, 1038–1041, doi: 10.1016/s0140-6736(88)91853-3.
38. Waghorn, D.J.; Kelly, T.W.; Gibbins, W. Epidemic multi-resistant *Escherichia coli* infection in south London. *Journal of Hospital Infection* **1988**, *11*, 192–193, doi: 10.1016/0195-6701(88)90063-1.
39. Wright, E.D.; Perinpanayagam, R.M. Multiresistant invasive *Escherichia coli* Infection in South London. *The Lancet* **1987**, *1*, 556–557, doi: 10.1016/S0140-6736(87)90190-5.
40. Manges, A.R.; Johnson, J.R. Reservoirs of extraintestinal pathogenic *Escherichia coli*. *Microbiology Spectrum* **2015**, *3*, doi: 10.1128/microbiolspec.UTI-0006-2012.
41. Hara-Kudo, Y.; Takatori, K. Contamination level and ingestion dose of foodborne pathogens associated with infections. *Epidemiology & Infection* **2011**, *139*, 1505–1510, doi: 10.1017/S095026881000292X.
42. Ewers, C.; Grobbel, M.; Stamm, I.; Kopp, P.A.; Diehl, I.; Semmler, T.; Fruth, A.; Beutlich, J.; Guerra, B.; Wieler, L.H.; Guenther, S. Emergence of human pandemic O25:H4-ST131 CTX-M-15 extended-spectrum-beta-lactamase-producing *Escherichia coli* among companion animals. *Journal of Antimicrobial Chemotherapy* **2010**, *65*, 651–660, doi: 10.1093/jac/dkq004.
43. Schaufler, K.; Semmler, T.; Wieler, L.H.; Trott, D.J.; Pitout, J.; Peirano, G.; Bonnedahl, J.; Dolejska, M.; Literak, I.; Fuchs, S.; Ahmed, N.; Grobbel, M.; Torres, C.; McNally, A.; Pickard, D.; Ewers, C.; Croucher, N.J.; Corander, J.; Guenther, S. Genomic and functional analysis of emerging virulent and multidrug-resistant *Escherichia coli* lineage sequence type 648. *Antimicrobial Agents and Chemotherapy* **2019**, *63*, e00243-00219, doi: 10.1128/AAC.00243-19.
44. Schaufler, K.; Semmler, T.; Wieler, L.H.; Wohrmann, M.; Baddam, R.; Ahmed, N.; Muller, K.; Kola, A.; Fruth, A.; Ewers, C.; Guenther, S. Clonal spread and interspecies transmission of clinically relevant ESBL-producing *Escherichia coli* of ST410—Another successful pandemic clone? *FEMS Microbiology Ecology* **2016**, *92*, doi: 10.1093/femsec/fiv155.



45. Skurnik, D.; Clermont, O.; Guillard, T.; Launay, A.; Danilchanka, O.; Pons, S.; Diancourt, L.; Lebreton, F.; Kadlec, K.; Roux, D.; Jiang, D.; Dion, S.; Aschard, H.; Denamur, M.; Cywes-Bentley, C.; Schwarz, S.; Tenaillon, O.; Andremont, A.; Picard, B.; Mekalanos, J.; Brisse, S.; Denamur, E. Emergence of antimicrobial-resistant *Escherichia coli* of animal origin spreading in humans. *Molecular Biology and Evolution* **2016**, *33*, 898–914, doi: 10.1093/molbev/msv280.
46. Abram, K.; Udaondo, Z.; Bleker, C.; Wanchai, V.; Wassenaar, T.M.; Robeson, M.S., 2nd; Ussery, D.W. Mash-based analyses of *Escherichia coli* genomes reveal 14 distinct phylogroups. *Communications Biology* **2021**, *4*, 117, doi: 10.1038/s42003-020-01626-5.
47. Lazarus, B.; Paterson, D.L.; Mollinger, J.L.; Rogers, B.A. Do human extraintestinal *Escherichia coli* infections resistant to expanded-spectrum cephalosporins originate from food-producing animals? A systematic review. *Clinical Infectious Diseases* **2015**, *60*, 439–452, doi: 10.1093/cid/ciu785.
48. Reid, C.J.; Cummins, M.L.; Borjesson, S.; Brouwer, M.S.M.; Hasman, H.; Hammerum, A.M.; Roer, L.; Hess, S.; Berendonk, T.; Nesporova, K.; Haenni, M.; Madec, J.Y.; Bethe, A.; Michael, G.B.; Schink, A.K.; Schwarz, S.; Dolejska, M.; Djordjevic, S.P. A role for ColV plasmids in the evolution of pathogenic *Escherichia coli* ST58. *Nature Communications* **2022**, *13*, 683, doi: 10.1038/s41467-022-28342-4.
49. Fuentes-Castillo, D.; Navas-Suarez, P.E.; Gondim, M.F.; Esposito, F.; Sacristan, C.; Fontana, H.; Fuga, B.; Piovani, C.; Kooij, R.; Lincopan, N.; Catao-Dias, J.L. Genomic characterization of multidrug-resistant ESBL-producing *Escherichia coli* ST58 causing fatal colibacillosis in critically endangered Brazilian merganser (*Mergus octosetaceus*). *Transbound Emerging Diseases* **2021**, *68*, 258–266, doi: 10.1111/tbed.13686.
50. Borges, C.A.; Tarlton, N.J.; Riley, L.W. *Escherichia coli* from commercial broiler and backyard chickens share sequence types, antimicrobial resistance profiles, and resistance genes with human extraintestinal pathogenic *Escherichia coli*. *Foodborne Pathogens and Disease* **2019**, *16*, 813–822, doi: 10.1089/fpd.2019.2680.
51. Carattoli, A. Plasmids in Gram negatives: Molecular typing of resistance plasmids. *International Journal of Medical Microbiology* **2011**, *301*, 654–658, doi: 10.1016/j.ijmm.2011.09.003.
52. Johnson, T.J.; Shepard, S.M.; Rivet, B.; Danzeisen, J.L.; Carattoli, A. Comparative genomics and phylogeny of the IncI1 plasmids: A common plasmid type among porcine enterotoxigenic *Escherichia coli*. *Plasmid* **2011**, *66*, 144–151, doi: 10.1016/j.plasmid.2011.07.003.
53. Smith, H.; Bossers, A.; Harders, F.; Wu, G.; Woodford, N.; Schwarz, S.; Guerra, B.; Rodriguez, I.; van Essen-Zandbergen, A.; Brouwer, M.; Mevius, D. Characterization of epidemic IncI1-I $\gamma$  plasmids harboring Ambler class A and C genes in *Escherichia coli* and *Salmonella enterica* from animals and humans. *Antimicrobial Agents and Chemotherapy* **2015**, *59*, 5357–5365, doi: 10.1128/AAC.05006-14.
54. Illumina. bcl-convert: A proprietary Illumina software for the conversion of bcl files to basecalls. [https://support-docs.illumina.com/SW/BCL\\_Convert/Content/SW/FrontPages/BCL\\_Convert.htm](https://support-docs.illumina.com/SW/BCL_Convert/Content/SW/FrontPages/BCL_Convert.htm) (accessed 07 March 2022).
55. Pribelski, A.; Antipov, D.; Meleshko, D.; Lapidus, A.; Korobeynikov, A. Using SPAdes de novo assembler. *Current Protocols in Bioinformatics* **2020**, *70*, e102, doi: 10.1002/cpbi.102.
56. Li, H.; Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **2009**, *25*, 1754–1760, doi: 10.1093/bioinformatics/btp324.
57. Li, H.; Handsaker, B.; Wysoker, A.; Fennell, T.; Ruan, J.; Homer, N.; Marth, G.; Abecasis, G.; Durbin, R.; Genome Project Data Processing, S. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **2009**, *25*, 2078–2079, doi: 10.1093/bioinformatics/btp352.
58. Walker, B.J.; Abeel, T.; Shea, T.; Priest, M.; Abouelliel, A.; Sakthikumar, S.; Cuomo, C.A.; Zeng, Q.; Wortman, J.; Young, S.K.; Earl, A.M. Pilon: An integrated tool for comprehensive microbial variant detection and genome assembly improvement. *PLOS One* **2014**, *9*, e112963, doi: 10.1371/journal.pone.0112963.
59. Parks, D.H.; Imelfort, M.; Skennerton, C.T.; Hugenholtz, P.; Tyson, G.W. CheckM: Assessing the quality of microbial genomes recovered from isolates, single cells, and metagenomes. *Genome Research* **2015**, *25*, 1043–1055, doi: 10.1101/gr.186072.114.
60. Seemann, T. Prokka: Rapid prokaryotic genome annotation. *Bioinformatics* **2014**, *30*, 2068–2069, doi: 10.1093/bioinformatics/btu153.
61. Jolley, K.A.; Bray, J.E.; Maiden, M.C.J. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. *Wellcome Open Research* **2018**, *3*, 124, doi: 10.12688/wellcomeopenres.14826.1.
62. Zhou, Z.; Alikhan, N.F.; Mohamed, K.; Fan, Y.; Agama Study, G.; Achtman, M. The Enterobase user's guide, with case studies on *Salmonella* transmissions, *Yersinia pestis* phylogeny, and *Escherichia coli* core genomic diversity. *Genome Research* **2020**, *30*, 138–152, doi: 10.1101/gr.251678.119.
63. Zankari, E.; Hasman, H.; Cosentino, S.; Vestergaard, M.; Rasmussen, S.; Lund, O.; Aarestrup, F.M.; Larsen, M.V. Identification of acquired antimicrobial resistance genes. *Journal of Antimicrobial Chemotherapy* **2012**, *67*, 2640–2644, doi: 10.1093/jac/dks261.
64. Pal, C.; Bengtsson-Palme, J.; Rensing, C.; Kristiansson, E.; Larsson, D.G. BacMet: Antibacterial biocide and metal resistance genes database. *Nucleic Acids Research* **2014**, *42*, D737–743, doi: 10.1093/nar/gkt1252.
65. Ingle, D.J.; Valcanis, M.; Kuzevski, A.; Tauschek, M.; Inouye, M.; Stinear, T.; Levine, M.M.; Robins-Browne, R.M.; Holt, K.E. In silico serotyping of *E. coli* from short read data identifies limited novel O-loci but extensive diversity of O:H serotype combinations within and between pathogenic lineages. *Microbial Genomics* **2016**, *2*, e000064, doi: 10.1099/mgen.0.000064.
66. Beghain, J.; Bridier-Nahmias, A.; Le Nagard, H.; Denamur, E.; Clermont, O. ClermonTyping: An easy-to-use and accurate in silico method for *Escherichia coli* genus strain phylotyping. *Microbial Genomics* **2018**, *4*, doi: 10.1099/mgen.0.000192.

67. Ondov, B.D.; Treangen, T.J.; Melsted, P.; Mallonee, A.B.; Bergman, N.H.; Koren, S.; Phillippy, A.M. Mash: Fast genome and metagenome distance estimation using MinHash. *Genome Biology* **2016**, *17*, 132, doi: 10.1186/s13059-016-0997-x.
68. Croucher, N.J.; Page, A.J.; Connor, T.R.; Delaney, A.J.; Keane, J.A.; Bentley, S.D.; Parkhill, J.; Harris, S.R. Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins. *Nucleic Acids Research* **2015**, *43*, e15, doi: 10.1093/nar/gku1196.
69. Page, A.J.; Taylor, B.; Delaney, A.J.; Soares, J.; Seemann, T.; Keane, J.A.; Harris, S.R. SNP-sites: rapid efficient extraction of SNPs from multi-FASTA alignments. *Microbial Genomics* **2016**, *2*, e000056, doi: 10.1099/mgen.0.000056.
70. Kozlov, A.M.; Darriba, D.; Flouri, T.; Morel, B.; Stamatakis, A. RAxML-NG: A fast, scalable and user-friendly tool for maximum likelihood phylogenetic inference. *Bioinformatics* **2019**, *35*, 4453–4455, doi: 10.1093/bioinformatics/btz305.
71. Letunic, I.; Bork, P. Interactive Tree Of Life (iTOL) v5: An online tool for phylogenetic tree display and annotation. *Nucleic Acids Research* **2021**, *49*, W293–W296, doi: 10.1093/nar/gkab301.
72. International Organization for Standardization. Part 1: Broth micro-dilution reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. In Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices. ISO 20776-1:2019. *International Organization for Standardization* **2019**.
73. Schaufler, K.; Semmler, T.; Pickard, D.J.; de Toro, M.; de la Cruz, F.; Wieler, L.H.; Ewers, C.; Guenther, S. Carriage of extended-spectrum beta-lactamase-plasmids does not reduce fitness but enhances virulence in some strains of pandemic *E. coli* lineages. *Frontiers in Microbiology* **2016**, *7*, 336, doi: 10.3389/fmicb.2016.00336.
74. Naves, P.; del Prado, G.; Huelves, L.; Gracia, M.; Ruiz, V.; Blanco, J.; Dahbi, G.; Blanco, M.; Ponte Mdel, C.; Soriano, F. Correlation between virulence factors and in vitro biofilm formation by *Escherichia coli* strains. *Microbial Pathogenesis* **2008**, *45*, 86–91, doi: 10.1016/j.micpath.2008.03.003.
75. Niu, C.; Gilbert, E.S. Colorimetric method for identifying plant essential oil components that affect biofilm formation and structure. *Applied and Environmental Microbiology* **2004**, *70*, 6951–6956, doi: 10.1128/AEM.70.12.6951-6956.2004.
76. Himpsl, S.D.; Mobley, H.L.T. Siderophore detection using chrome azurol S and cross-feeding assays. *Methods in Molecular Biology* **2019**, *2021*, 97–108, doi: 10.1007/978-1-4939-9601-8\_10.
77. Arora, N.K.; Verma, M. Modified microplate method for rapid and efficient estimation of siderophore produced by bacteria. *3 Biotech* **2017**, *7*, 381, doi: 10.1007/s13205-017-1008-y.
78. Ewers, C.; Antão, E.M.; Diehl, I.; Philipp, H.C.; Wieler, L.H. Intestine and environment of the chicken as reservoirs for extraintestinal pathogenic *Escherichia coli* strains with zoonotic potential. *Applied and Environmental Microbiology* **2009**, *75*, 184–192, doi: 10.1128/AEM.01324-08.
79. Schierack, P.; Heiden, S.E.; Khan, M.M.; Nikolaus, L.; Kolenda, R.; Stubbe, M.; Lkhagvasuren, D.; Rodiger, S.; Guenther, S.; Schaufler, K. Genomic and phenotypic analysis of an ESBL-producing *E. coli* ST1159 clonal lineage from wild birds in Mongolia. *Frontiers in Microbiology* **2020**, *11*, 1699, doi: 10.3389/fmicb.2020.01699.
80. Kaplan, E.L.; Meier, P. Nonparametric estimation from incomplete observations. *Journal of the American Statistical Association* **1958**, *53*, 457–481, doi: 10.1080/01621459.1958.10501452.